ReviewClinical and experimental medicine2023
The role and function of CLU in cancer biology and therapy.
Review in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 31 citations in OpenAlex.
- Tumor Clusterin Expression at Diagnosis Is Associated with Residual Disease Burden After Neoadjuvant Chemotherapy in Breast Cancer.Journal of clinical medicine · 2026Article
- A Proteomic Atlas of Human Milk: Uncovering Milk Functional Components.Research square · 2026Article
- Core Values: Does Clusterin Functionally Link HCV Core Protein Signaling to Malignant Phenotypes in HCV-Associated HCC?Digestive diseases and sciences · 2026Article
- Article
- Silencing Clusterin Could Attenuate the Cell Properties of HCV Core Protein-Expressing HCC Cell Line.Digestive diseases and sciences · 2026Article
- Therapeutic strategy for cervical gastric-type adenocarcinoma by targeting CLU to relieve CLU-associated stress and sensitize chemotherapy.Precision clinical medicine · 2026Article
- Clusterin Promotes the Migration and Invasion of Highly Aggressive Breast Cancer Cells Through Molecular Mechanisms That Affect the Cell Cytoskeleton and Extracellular Matrix Dynamics.International journal of molecular sciences · 2026Article
- Tumor-secreted clusterin promotes cachectic fat wasting via disrupting circadian gene expression and adipogenesis.The EMBO journal · 2026Article
- A diagnostic signature derived from NK cell related genes in prostate cancer: insights from integrated scRNA-seq and bulk RNA-seq analyses with functional validation of KIT.Frontiers in immunology · 2026Article
- Exploring the regulatory mechanisms of paraptosis-related prognostic genes in gastric cancer using single-cell sequencing and transcriptome analysis.Scientific reports · 2025Article
- Investigating the Development of Colorectal Cancer Based on Spatial Transcriptomics.International journal of molecular sciences · 2025Article
- Article
- Article
- LTF as a Potential Prognostic and Immunological Biomarker in Glioblastoma.Biochemical genetics · 2025Article
- Clusterin facilitates glioma progression via BCL2L1-dependent regulation of apoptotic resistance.Frontiers in molecular neuroscience · 2025Article
- Clusterin: structure, function and roles in disease.International journal of medical sciences · 2025Review
- Clusterin mediates hydroquinone-induced cytotoxic responses in HL-60 differentiated cells.Scientific reports · 2024Article
- Review
- Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure.BMC urology · 2024Article
- Clusterin: a double-edged sword in cancer and neurological disorders.EXCLI journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Clusterin (CLU) is a highly evolutionary conserved glycoprotein with multiple isoform-specific functions and is widely distributed in different species. Accumulated evidence has shown the prominent role of CLU in regulating several essential physiological processes, including programmed cell death, metastasis, invasion, proliferation and cell growth via regulating diverse signaling pathways to mediate cancer progression in various cancers, such as prostate, breast, lung, liver, colon, bladder and pancreatic cancer. Several studies have revealed the potential benefit of inhibiting CLU in CLU inhibition-based targeted cancer therapies in vitro, in vivo or in human, suggesting CLU is a promising therapeutic target. This review discusses the multiple functions and mechanisms of CLU in regulating tumor progression of various cancers and summarizes the inhibitors of CLU used in CLU inhibition-based targeted cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.